Here are the 10-K annual reports from Biofrontera Inc. Warrants (BFRIW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow BFRIW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BFRIW filings page.
Biofrontera Inc., a Delaware corporation listed on Nasdaq under the symbol BFRI, has filed Amendment No. 1 to its Original 10-K for the year ended December 31, 2025. The amendment is narrowly focused on updating the exhibit index.
The changes primarily add the company’s Amended and Restated Bylaws as Exhibit 3.3 and make other minor exhibit-index adjustments. It also includes new principal executive officer and principal financial officer certifications under Section 302 of the Sarbanes-Oxley Act, with certain paragraphs omitted because no financial statements are included.
No financial statements or internal control disclosures are revised, and events after the Original 10-K filing date are not reflected. As of June 30, 2025, the aggregate market value of common stock held by non-affiliates was $6.9 million, and 11,648,323 common shares were outstanding as of March 16, 2026.
Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on photodynamic therapy for dermatology, led by its Ameluz drug used with RhodoLED lamps to treat actinic keratosis. A key milestone was an October 20, 2025 strategic transaction through which it acquired all U.S. rights to Ameluz and RhodoLED from the Biofrontera Group, shifting control of manufacturing, clinical development and regulatory assets to the company. Biofrontera is pursuing label expansions, including superficial basal cell carcinoma, moderate to severe acne, and actinic keratosis on the trunk and extremities, with an sBCC supplemental NDA accepted by the FDA and a PDUFA date of September 28, 2026. A new Ameluz formulation without propylene glycol, backed by a U.S. patent expiring in 2043, has been implemented in U.S. production. As of December 31, 2025, the company had 92 employees and no single customer represented more than 10% of receivables or revenue. The filing highlights substantial regulatory, reimbursement, manufacturing, intellectual property, financing and going-concern risks.